NASDAQ STOPS TRADING OF OSCIENT STOCK FOLLOWING FDA NEWS

The fate of the company's drug, Factive, is in the hands of the Anti-Infective Drug Advisory Committee, which is an advisory committee to the U.S. Food and Drug Administration. The committee is scheduled to report on the company's request to expand the drug's offering. The drug is used to fight bronchitis and pneumonia, but Oscient is seeking to get approval to use the drug to treat sinus infections, company officials report.

Mass High Tech (http://www.bizjournals.com/masshightech/stories/2006/09/11/daily22.html?from_rss=1)